Reduced efficacy of treatment of strongyloidiasis in HTLV-I carriers related to enhanced expression of IFN-gamma and TGF-beta1.
about
Strongyloides hyperinfection syndrome: an emerging global infectious diseaseRegulatory T cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen.Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality in vivoStrongyloides stercoralis: Global Distribution and Risk FactorsFive cases of recurrent meningitis associated with chronic strongyloidiasis.Strongyloides stercoralis in the Immunocompromised PopulationEpidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis.Strongyloides stercoralis infection in the immunocompromised host.Update on strongyloidiasis in the immunocompromised host.Occurrence of strongyloidiasis among patients with HTLV-1/2 seen at the outpatient clinic of the Núcleo de Medicina Tropical, Belém, State of Pará, Brazil.Seroepidemiology of Strongyloides stercoralis in Dhaka, Bangladesh.Human T-cell leukemia virus type I infects human lung epithelial cells and induces gene expression of cytokines, chemokines and cell adhesion molecules.Clinical conditions associated with intestinal strongyloidiasis in Rio de Janeiro, Brazil.HTLV-1 modifies the clinical and immunological response to schistosomiasis.Importance of a Rapid and Accurate Diagnosis in Strongyloides Stercoralis and Human T-Lymphotropic Virus 1 Co-infection: A Case Report and Review of the Literature.HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment.[Combined infection with HTLV-1 and Strongyloides stercoralis].
P2860
Q28271599-A81E3BC9-7E8D-41D4-981B-BF7C24F083F4Q33464929-7C521D8B-5857-4082-BC46-8AC39B4F7DA8Q34671871-88E113FA-DE2C-4935-8611-C8128DF82F16Q34855113-7BB59528-9706-452A-8E81-802CBB26683FQ35150339-618E6583-C679-4D62-821F-7F5D11B7FBBCQ35545577-76FF53B4-CEE3-4570-9F45-BB489C6B3680Q36072562-D10ED05B-1317-4B5F-A558-4EFCA4B5D826Q36107292-22795A8E-6A4C-4862-9060-67B5F65C70FEQ37838791-3E892559-2E88-4059-8D18-06F933C4061FQ39014281-7A3951CC-CFFA-4C5F-9162-51C3E9EA3DC9Q39497635-8E866E18-CFCB-4083-A139-B8DC25C8EE16Q39937243-FAF27C25-0A18-4334-8EB4-1E7C9DFA1A8BQ41141954-F532C47D-2A89-46D4-9994-B53FAEE28281Q44990883-51D99572-FE5B-4AA3-88B8-B62EE05E848BQ47098391-F15336CA-A8FC-41CD-A13D-9BA01EF7C1EEQ47562043-AD5EF611-133F-42B1-B421-63D9B61A229CQ55239247-963A2BD1-4748-4E77-AFF0-A15DC7B45B14
P2860
Reduced efficacy of treatment of strongyloidiasis in HTLV-I carriers related to enhanced expression of IFN-gamma and TGF-beta1.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Reduced efficacy of treatment ...... on of IFN-gamma and TGF-beta1.
@en
Reduced efficacy of treatment ...... on of IFN-gamma and TGF-beta1.
@nl
type
label
Reduced efficacy of treatment ...... on of IFN-gamma and TGF-beta1.
@en
Reduced efficacy of treatment ...... on of IFN-gamma and TGF-beta1.
@nl
prefLabel
Reduced efficacy of treatment ...... on of IFN-gamma and TGF-beta1.
@en
Reduced efficacy of treatment ...... on of IFN-gamma and TGF-beta1.
@nl
P2093
P2860
P1476
Reduced efficacy of treatment ...... on of IFN-gamma and TGF-beta1.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2249.2002.01733.X
P577
2002-02-01T00:00:00Z